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What should the C (‘congestive heart failure’)
represent in the CHA2DS2-VASc score?
Bart A. Mulder* , Dirk J. van Veldhuisen, and Michiel Rienstra
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Introduction
Patients with atrial fibrillation (AF) require anticoagulation therapy
when at least two clinical risk factors for stroke or thromboem-
bolism are present, as defined in the CHA2DS2-VASc score.
1 In
this score the C stands for ‘congestive heart failure’ and nowa-
days the criteria to qualify for a C in clinical practice are more
or less synonymous to the presence of signs/symptoms of heart
failure.1 The criteria for the CHA2DS2-VASc score were, however,
defined and developed at a time when heart failure was more or
less restricted to patients who had left ventricular systolic dysfunc-
tion [or reduced left ventricular ejection fraction (LVEF)]. Whether
these criteria also apply to patients who have heart failure with
preserved ejection fraction (HFpEF), i.e. whether the C in the
CHA2DS2-VASc score also ‘counts’ in this population, is however
unknown.2 This is of interest as an increasing proportion of patients
with heart failure have HFpEF, AF is more common in HFpEF and
these patients have a similar increased risk for stroke or cardiovas-
cular events.3–5 Diagnosing HFpEF has been increasingly important
but remains challenging as compared to diagnosing a heart failure
with a reduced ejection fraction (HFrEF). This viewpoint will focus
on the history of the C in the CHA2DS2-VASc score and why it
may or may not be considered to extrapolate the CHA2DS2-VASc
criteria to patients with HFpEF and AF as well.
History of the C in the
CHA2DS2-VASc score
In patients with AF, who have a CHA2DS2-VASc risk score of
≥2 (points) in men, and ≥3 (points) in women, anticoagulation
therapy is generally recommended (class IA recommendation in
the European Society of Cardiology AF management guidelines).1
The clinical characteristics from which the CHA2DS2-VASc score is
derived are, however, all based on registry data.6 This is important
to realize, since the definition for heart failure has evolved over
recent years.3 First, the term generally used nowadays is no longer
‘congestive’ heart failure, but rather ‘chronic’ heart failure, which
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.. is related to the fact that not all patients have obvious signs of
congestion and also the distinction is primarily made between acute
and chronic heart failure. Second, and more importantly, since
2016 heart failure is categorized into three groups based on LVEF:
reduced (<40%), mid-range (40–49%) and preserved (>50%). In
the first description of the CHADS2 score, the precursor of
the CHA2DS2-VASc score, the C was classified as recent (i.e. in
the last 100 days in one of the studies7) congestive heart failure
exacerbation (without a LVEF criterium).8 The CHA2DS2-VASc
score is based on the CHADS2 score and uses the same definitions.
In the first paper by Lip et al.6 proposing the CHA2DS2-VASc score,
the Euro Heart Survey was used as a validation cohort, where
congestive heart failure was classified as ‘heart failure’ or ‘left
ventricular ejection below 35%’. The group ‘heart failure’ in that
study is possibly reflecting patients with symptoms of heart failure,
with and without reduced ejection fraction, so it may be suggested
that also HFpEF patients were included, although these data are
not reported.
Stroke prediction risk scores
in atrial fibrillation
The CHADS2 and CHA2DS2-VASc scores were not the first (and
not the last) attempts for a reliable stroke prediction risk score
in AF.9 The CHADS2 score was the result of previous risk scoring
models, namely the Atrial Fibrillation Investigators (AFI) scheme
and the Stroke Prevention and Atrial Fibrillation (SPAF) scheme.7
In the AFI risk scheme, data were collected from five other trials: (i)
the Atrial Fibrillation, Aspirin, Anticoagulation Study from Copen-
hagen, Denmark (AFASAK), (ii) the Stroke Prevention in Atrial
Fibrillation (SPAF) study, (iii) the Boston Area Anticoagulation Trial
in Atrial Fibrillation (BAATAF), (iv) the Canadian Atrial Fibrilla-
tion Anticoagulation (CAFA) study, and (v) the Veterans Affairs
Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF)
study. Congestive heart failure was considered as a risk factor, but
was not qualified similarly amongst the studies (see Table 1 for an
overview of the studies). For example, in the AFASAK trial only
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
2 Viewpoint
Table 1 Overview of the definition of heart failure as the basis for the C in CHA2DS2-VASc
Study Definition of ‘heart failure’ in this study LVEF of heart
failure patients
Incorporated in AFI,
CHADS2, CHA2DS2−VASc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
AFASAK Symptoms of heart failure (non specified) Not reported Yes
SPAF History of congestive heart failure Not reported Yes
BAATAF History of congestive heart failure Not reported Yes
CAFA Heart failure (non specified) Not reported Yes
SPINAF History of congestive heart failure Not reported Yes
AFASAK, Atrial Fibrillation, Aspirin, Anticoagulation Study from Copenhagen, Denmark; AFI, Atrial Fibrillation Investigators; BAATAF, Boston Area Anticoagulation Trial in
Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation Anticoagulation; LVEF, left ventricular ejection fraction; SPAF, Stroke Prevention in Atrial Fibrillation; SPINAF, Veterans
Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation.
patients with symptomatic moderate and severe heart failure were
considered to have congestive heart failure.10 Notably, no data on
LVEF were provided in any of these trials and it is uncertain what
type of heart failure these patients really had (reduced, mid ranged
or preserved LVEF). It appears, however, that from a historical per-
spective, many of these patients must have been HFrEF patients.3 In
conclusion, in the original cohorts, predominantly HFrEF patients
were included as HFpEF was not acknowledged at that time. There-
fore, the C of congestive heart failure, appears to be primarily
driven by HFrEF.
Pathophysiology of atrial
fibrillation-related stroke in heart
failure with preserved
and reduced ejection fraction
For HFpEF and HFrEF the same pathophysiology processes are
contributing to Virchow’s pre-requisites for thrombosis: abnormal
blood flow, abnormalities in the blood vessel wall, and abnormal
blood constituents (Figure 1).11,12 Constituent abnormalities are
present in the form of abnormal platelets and increased levels
of pro-thrombotic markers.11 While the level of many circulating
biomarkers increases with severity or worsening of heart failure, as
is the case for e.g. the level of plasminogen activator inhibitor and
tissue plasminogen activator antigen, both markers of fibrinolysis
are elevated in heart failure patients across a wide range of LVEF,
and regardless of LVEF.11,13
Stroke risk in heart failure
regardless of left ventricular
ejection fraction
The risk of stroke is significantly increased in patients with any
reduction in LVEF and increases with a high CHA2DS2-VASc
score.14 The influence of LVEF on stroke risk appears to be
substantial.13,15 Recent data, however, suggest that the stroke risk is
similarly increased in patients with reduced and preserved LVEF.16
A sub-analysis of patients (from the non-oral anticoagulation arm) .
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. participating in the Atrial Fibrillation Clopidogrel Trial With Irbe-
sartan for Prevention of Vascular Events (ACTIVE) trials who also
had heart failure were categorized as having preserved vs. reduced
ejection fraction.16 Data from this study showed that the stroke
risk was comparable between the two groups: 4.3% (in patients
with HFpEF) and 4.4% (in HFrEF) per 100 person-years.16 In addi-
tion, a meta-analysis incorporating seven studies with a total of
33 773 patients with heart failure showed that for patients with
HFrEF and HFpEF who also had AF the rate of stroke risk was
similar at 1.6% in HFrEF and 1.3% in HFpEF (relative risk 0.85,
P = 0.094).15
Prevention of atrial
fibrillation-related stroke in heart
failure regardless of left
ventricular ejection fraction
The most recent AF guidelines do not further differentiate the C
(congestive heart failure) in the CHA2DS2-VASc score, and score
the ‘C’ when patients have signs/symptoms of heart failure or
objective evidence of reduced LVEF. Indeed, there is no mention
of HFpEF with regard to stroke prevention and as a result patients
with HFpEF possibly must have more symptoms to receive anti-
coagulation (since they do not qualify with the LVEF criterium)
than those with HFrEF. In the most recent heart failure guide-
lines it is stated that patients with heart failure (non-specified)
and in New York Heart Association (NYHA) functional class II–IV
should be considered for anticoagulation, if eligible, as assessed
by the CHA2DS2-VASc score. Data on efficacy and safety of
anticoagulation in heart failure patients have been published in
several post-hoc analyses of the landmark novel oral anticoag-
ulant (NOAC) trials.17–19 In the heart failure substudy of the
ROCKET-AF trial, heart failure was defined as a history of heart
failure (non-specified) or a LVEF <40%.17 In the ARISTOTLE heart
failure substudy, two groups of heart failure were defined. Patients
with left ventricular systolic dysfunction (defined as LVEF <40%,
or a documentation of moderate or severe left ventricular sys-
tolic dysfunction) with or without symptomatic heart failure. Or
the second group which were heart failure patients who had
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Viewpoint 3
Figure 1 Hypothesis generating figure of the relation of stroke and heart failure. Illustrating that heart failure with preserved (HFpEF)
and reduced ejection fraction (HFrEF) share similar risk factors for stroke using Virchow’s triad. BMI, body mass index; RAAS,
renin–angiotensin–aldosterone system.
symptomatic heart failure and LVEF >40%, normal left ventricu-
lar function, or mild left ventricular systolic dysfunction, grouped
as HFpEF.18 In the RE-LY trial, heart failure was defined as the
presence of NYHA class II or higher in the 6 months before screen-
ing, in patients with a history of previous admission for congestive
heart failure. Information about LVEF was available in only 2889
patients with heart failure (58.9%).19 A total 43.5% of the heart
failure patients had a LVEF <40%, which may suggest that 56.5%
of patients in the RE-LY heart failure group had HFpEF (or that
no measurement was available). In the ENGAGE AF-TIMI 48 study,
heart failure was defined as current presence or history of heart
failure class C or D according to the American Heart Associa-
tion/American College of Cardiology definition. In this study, 49%
of patients had LVEF <50%, implying that half of the heart failure
patients were HFpEF (of which many were classified as severe heart
failure).20 Figure 2 shows the percentages of stroke in the heart
failure groups and illustrates that in the heart failure population
a significant proportion of patients had HFpEF. Overall the con-
clusions of these post-hoc NOAC papers were that the effect of
NOACs in patients with heart failure and AF is similar, both for
efficacy as well as for safety outcomes as compared to AF patients
without heart failure. Although one should be cautious to draw
strong conclusions from the above studies in patients with HFpEF, .
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Figure 2 Percentages of stroke in heart failure patients in the
four major novel oral anticoagulant trials. HFpEF, heart failure
with preserved ejection fraction; LVEF, left ventricular ejection
fraction; LVSD, left ventricular systolic dysfunction.
these recommendations have in fact been made (from the historical
data) for patients with HFrEF. 17–20
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
4 Viewpoint
Summary
Given the recent increase in HFpEF and the fact that the
CHA2DS2-VASc is (mainly) based on HFrEF, criteria for anticoagu-
lation for AF and HFpEF are in reality lacking. This is remarkable,
given the fact that AF is more common in patients with HFpEF.
However, as long as there are no trials performed specifically in
this HFpEF population and there is no pathophysiological reason
why data would be different in HFpEF, we believe that given the
available data, anticoagulation must be seriously considered in
many patients with AF and HFpEF. Indeed, recommendations for
anticoagulation in AF/HFpEF patients may possibly be similar to
those for HFrEF.
Conflict of interest: none declared.
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